Tumor Necrosis Factor α Regulates Endothelial Progenitor Cell Migration via CADM1 and NF-κB

ANTHONY R. PRISCO,a,b BRIAN R. HOFFMANN,b,c,d CATHERINE C. KACZOROWSKI,e CHRIS McDERMOTT-ROE,a,f TIMOTHY J. STODOLA,a,b ERIC C. EKNER,a,b ANDREW S. GREENE,a,b

Key Words. Endothelial progenitor cells • CADM1 • TNFα • Cellular migration

ABSTRACT

Shortly after the discovery of endothelial progenitor cells (EPCs) in 1997, many clinical trials were conducted using EPCs as a cellular based therapy with the goal of restoring damaged organ function by inducing growth of new blood vessels (angiogenesis). Results were disappointing, largely because the cellular and molecular mechanisms of EPC-induced angiogenesis were not clearly understood. Following injection, EPCs must migrate to the target tissue and engraft prior to induction of angiogenesis. In this study EPC migration was investigated in response to tumor necrosis factor α (TNFα), a pro-inflammatory cytokine, to test the hypothesis that organ damage observed in ischemic diseases induces an inflammatory signal that is important for EPC homing. In this study, EPC migration and incorporation were modeled in vitro using a coculture assay where TNFα treated EPCs were tracked while migrating toward vessel-like structures. It was found that TNFα treatment of EPCs increased migration and incorporation into vessel-like structures. Using a combination of genomic and proteomic approaches, NF-κB mediated upregulation of CADM1 was identified as a mechanism of TNFα induced migration. Inhibition of NF-κB or CADM1 significantly decreased migration of EPCs in vitro suggesting a role for TNFα signaling in EPC homing during tissue repair. STEM CELLS 2016;34:1922–1933

SIGNIFICANCE STATEMENT

Endothelial progenitor cells (EPCs) have been shown to regenerate blood vessels in animal studies. Human trials have not yet demonstrated therapeutic efficacy as the molecular regenerative mechanisms are poorly understood. In this study, it was discovered that EPC migration toward vessels is increased in the presence of the inflammatory signal, TNFα. A combined genomic and proteomic analysis was used to propose and validate a mechanism of TNFα-mediated migration. These results suggest that the protein CADM1 mediates TNFα-mediated EPC migration toward vessels. In humans, CADM1 SNPs have been associated with vascular disease/dysfunction, confirming the importance of this mechanism clinically.

INTRODUCTION

The discovery of endothelial progenitor cells (EPCs) and the first demonstration that a cellular based therapy could be used as a regenerative therapeutic was published by Asahara and colleagues in 1997 [1]. Successful use of EPCs in animal models to regenerate lost organ function prompted the initiation of human trials [2, 3]. Conflicting results from human trials raised notable concern regarding the efficacy of using EPCs to restore organ function [4, 5]. The prevailing explanation of these results was based on the observation that the cell population that was used to induce regeneration was derived from autologous donors. It was hypothesized that because the cells were isolated from individuals with cardiovascular disease, the cells were therapeutically incompetent as a result of the underlying pathophysiology. Very little data exists supporting this hypothesis as the molecular mechanisms of EPC-induced angiogenesis are not well understood. Therefore, development of an effective cellular-based therapy requires a better understanding of the cellular mechanisms of regeneration.

EPCs are primarily found in the bone marrow, peripheral circulation, and vessel walls with the majority being in the bone marrow [6]. It has been demonstrated that EPCs are mobilized out of the bone marrow to sites of ischemia in order to repair damage [7]. Many groups have studied the mobilization of EPCs, associating acute inflammation with increased EPC mobilization [8, 9]. The majority of human disease states induce an inflammatory response [10]. It is well

STEM CELLS 2016;34:1922–1933 www.StemCells.com © 2016 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
understood that immune cells are recruited to an active site of disease, illness, or infection and can induce apoptosis in infected cells, collect debris, and provide support for repair. EPCs and immune cells share a common precursor, so it is likely they play an innate regenerative role [1]. For example, acute events such as myocardial infarction, stroke, and dilated cardiomyopathy increase the number of peripheral EPCs [11–13]. In these studies, patients observed with a higher number of peripheral EPCs typically exhibited better outcomes than patients with a lower number of peripheral EPCs. In contrast, patients with chronic diseases typically have decreased numbers of peripheral EPCs and poorer outcomes [14–16].

We hypothesized that repair of organ damage by endogenous EPCs functions as a feedback controlled system to maintain tissue integrity (Fig. 1). In such a system, an acute injury would induce the production of pro-inflammatory cytokines that would act to both mobilize EPCs from the bone marrow and recruit EPCs from the circulation to the target tissue. Recruitment of cells and repair of damaged tissue would thereby decrease the injury signal completing the feedback loop.

In this study, Tumor Necrosis Factor (TNFα) was used as the prototypic pro-inflammatory cytokine to induce EPC migration as others have demonstrated the role of TNFα in activation of EPC function [19–21]. Kelly et al. demonstrated that TNFα receptors play a key role in stem cell-mediated regeneration of cardiac function [22]. TNFα is a pro-inflammatory cytokine that acts primarily to regulate immune cell function including rolling, adhesion, proliferation, and apoptosis [23–30]. To increase localized recruitment of leukocytes during an inflammatory response, TNFα simulation of the endothelium increases the number of adhesive molecules expressed on the cell surface [31]. In addition to production of TNFα in response to a foreign antigen, TNFα is produced in response to other stimuli, for example, during exercise or in traumatic injury [32–35]. Because TNFα has known roles in cellular recruitment, adhesion and remodeling, it was hypothesized that acute, low-dose treatment would increase the migratory properties of EPCs to vascular endothelial cells.

The EPC mobilization process has been very well studied and characterized. The process by which EPCs migrate to a damaged tissue following an insult or injection (Fig. 1) has not been well studied. Elucidation of mechanisms that control migration of EPCs to damaged tissue could provide insight into approaches to augment the repair process induced by endogenous EPCs. Additionally, assessment of cells prior to treatment could help predict the likelihood of successful therapy.

While the importance of TNF signaling in tissue regeneration has been demonstrated, studies have typically quantified high-level phenotypes such as cardiac function in response to sequentially deleting TNF receptors. The goal of this manuscript was to investigate the cellular functions and associated molecular mechanisms that occur after injection of EPCs, specifically those that control EPC migration to target areas of the vasculature in response to TNFα. To accomplish this, a comprehensive approach was developed where TNFα-induced signaling was analyzed in 3 parts: (1) receptors, (2) effectors, and (3) intracellular signaling. Experiments were designed to elucidate the molecular mechanisms at each level. At the receptor level, TNFα signaling is a well characterized process; however, there are multiple TNF receptors and pathway effects. To determine the mechanism of TNF receptor signaling (Part 1) in EPCs, gene expression of key TNFα signaling components was following treatment. To determine potential effector proteins (Part 2), liquid chromatography tandem-mass spectrometry (LC/MS-MS) was used to identify candidate proteins that were differentially regulated in response to TNFα stimulation and that were consistent with observed receptor

---

**Figure 1.** Bone marrow stem cell repair axis. EPCs are transported from the bone marrow to the myocardium. Injured myocardium releases inflammatory signals that mobilize EPCs from the bone marrow. Cells are released into the circulation and blood flow through damaged organs induces recruitment of cells to target tissue. These cells can then repair the damaged myocardium and suppress the inflammatory signal, completing the feedback loop. Abbreviations: EPCs, endothelial progenitor cells.
signaling. To determine the specific mechanisms of intracellular signaling, candidate proteins and signaling pathway members were inhibited and EPC migration was evaluated in response to TNFα (Part 3). In conducting these studies, a new molecular mechanism of TNFα-induced migration was proposed, tested, and validated.

**MATERIALS AND METHODS**

**Electrically-Stimulated Model of Hindlimb Angiogenesis**

The Medical College of Wisconsin (MCW) Institutional Animal Care and Use Committee approved all animal protocols. Sprague Dawley rats were placed on 4% salt diet one week before surgery to suppress angiogenesis [36]. Nine- to ten-week-old rats were anesthetized with an intramuscular injection mixture of ketamine (70 mg/kg), Xylazine (4 mg/kg) and Acepromazine (1 mg/kg). Aseptically, a battery-powered stimulator was implanted on the medial right limb [37]. Electrodes induced contractions of the tibialis anterior (TA) and extensor digitorum longus (EDL) muscles for eight consecutive hours, daily. The contralateral leg was used as a control. All animals were euthanized after seven days of stimulation and expression of TNFα was measured via PCR and ELISA.

**EPC Isolation and In Vivo Expansion**

EPCs were isolated from Sprague Dawley (SD) rat (Harlan, Indianapolis, Indiana; http://www.harlan.com) tibia/femur bone marrow as previously described [19, 38]. SD rats were euthanized, the tibia/femur were isolated, and the bone marrow was flushed using a 20 gauge needle. The RBCs were separated from the bone marrow using a polysucrose solution and differential centrifugation (Histopaque 1083; Sigma-Aldrich 10831, St. Louis, Missouri; http://www.sigma-aldrich.com). The mononuclear fraction was collected, washed, and seeded at a density of 1 × 10⁷ cells/dish onto fibronectin coated (10 µg/ml) cell culture dishes. Cells were cultured in MCDB131 (E3000-01B; US Biological; Swampscott, MA, http://www.usbio.net) supplemented with 10% fetal bovine serum (FBS) and the endothelial cell growth media 2 (EGM-2) supplement pack (Lonza, Basel, Switzerland; http://www.lonza.com). Cells were grown at 37°C, 20% O₂, and 5% CO₂.

**Cell Culture**

Rat cardiac microvascular endothelial cells (RCMVECs) were plated, expanded (P4-P6) in 100 mm dishes (R1111; Cell Biologics; Chicago, IL, http://www.cellbiologics.net) and cultured to confluence in endothelial cell media (MCDB131, E3000-01B; US Biological, Swampscott, MA; http://www.usbio.net) with the EGM-MV pack (CC-4147; Lonza, Basel, Switzerland, http://www.lonza.com). Cells were oxidized by adding 4 ml of 1mM sodium-meta-periodate (Sigma-Aldrich 10831, St. Louis, Missouri; http://www.sigma-aldrich.com). The oxidized glycans were labeled at 4°C with TS-100 micrograph 2 hours and 14 hours following EPC seeding (initial studies revealed that assessment at 2 hours is the earliest time point repeatable results can be demonstrated, assessment at 14 hours is the latest time point before results become inconsistent). The number and locations of fluorescent EPCs were detected/recorded. These locations were registered against the bright field images of tube-like structures and the number of cells that had migrated to tubes was determined [39]. The ratio of incorporated versus total EPCs was calculated and compared across groups.

**qPCR Results and Analysis**

Expression of genes in the TNFα pathway was measured using the RT2 Profiler™ PCR Array (Qiagen; PARN-0632, Venlo, Netherlands; http://www.qiagen.com). EPCs were treated with TNFα (1 ng/ml) or vehicle (PBS) for 3 hours. RNA was isolated using the RNeasy Mini-Kit (QIAGEN, Cat. # 47104, Venlo, Netherlands; http://www.qiagen.com) and converted to cDNA using the RT2 First Strand Kit (QIAGEN 330401, Venlo, Netherlands; http://www.qiagen.com). Samples were run on a 7900HT Real-Time PCR Thermocycler (Invitrogen, Waltham, Massachusetts; http://www.thermofisher.com) and analyzed using QIAGEN software.

Cadm-1 qPCR was done by loading 50 ng of RNA/well into a 1X solution of TaqMan Fast Virus 1-Step Master Mix (Invitrogen 4444432, Waltham, Massachusetts; http://www.thermofisher.com) with validated CADM-1 primers (Life Technologies Rn00457556_m1, Thermo Fisher Scientific; Waltham, Massachusetts; http://www.thermofisher.com). 18S ribosomal subunit (Invitrogen 4333760F, Waltham, Massachusetts; http://www.thermofisher.com) was used as the control gene, data were analyze via the Livak and Schmittgen method and expressed as relative transcript abundance.

**TNFα ELISA**

TNFα levels in unstimulated/stimulated skeletal muscle homogenates were measured with an ELISA kit (Invitrogen KRC3011, Waltham, Massachusetts; http://www.thermofisher.com). Skeletal muscle was disrupted in 500 µl buffer with a protease inhibitor (Roche 11697498001, Basel, Switzerland; http://www.roche.com) and 0.5% Triton X-100 in PBS with a TissueLyser II (Qiagen, Venlo, Netherlands; http://www.qiagen.com). Total protein concentration was determined using Bio-Rad DC protein assay and lysates were analyzed for TNFα.

**Proteomics Results**

Cell surface proteins were identified following chemical isolation using LC-MS/MS. EPC surface proteins were isolated using a combination of two separate chemical isolation methods, both as described previously, a glycoprotein isolation (Cell Surface Capture, CSC) [40] and a cell membrane associated biotinylation isolation (CMABI) [41].

To isolate using the CSC method, surface glycoproteins were oxidized by adding 4 ml of 1mM sodium-meta-periodate (Fisher, PI20504, Fisher Scientific; Hampton, New Hampshire; http://www.fishersci.com) at 4°C for 15 minutes. Cells were lifted using an enzyme free dissociation buffer (Millipore, S-014-B, Merck Millipore; Billerica, Massachusetts; http://www.emdmillipore.com). Oxidized glycans were labeled at 4°C for
60 minutes using 4 ml of 10 mM biocytin hydrazide (Biotium, 90060, Biotium, Inc; Hayward, CA; http://www.biotium.com). EPCs were lysed and the membrane fraction was pelleted at 35,000xg. The membrane fraction was reduced for 30 minutes (100 mM, NaHCO3; 0.1% RapiGest, 5mM TCEP) and alkylated for 30 minutes in iodoacetamide (10 mM). Samples were digested for 18 hours and peptides labeled with the oxidized glycan modification were purified and analyzed using an LTQ Orbitrap Velos Mass Spectrometer.

To isolate using the CMABi method, EPCs were lifted from culture dishes using an enzyme free dissociation buffer (Millipore, S-014-B, Merck Millipore; Billerica, Massachusetts; http://www.emdmillipore.com) at 4°C for 45 minutes. Cells were washed, pelleted, resuspended and labeled using 4 ml of 1 mM NHS-SS-Biotin for 60 minutes. Cells were lysed and membrane fractions were separated at 55,000xg for 2 hours at 4°C. Samples were digested using trypsin for 18 hours. Peptides labeled with the NHS-SS-Biotin modification were isolated using streptavidin coated beads (Pierce, 53117, Thermo Fisher Scientific; Waltham, Massachusetts; http://www.thermofisher.com). Samples were then washed, reduced, (100 mM, NaHCO3; 0.1% RapiGest, 5mM TCEP), alkylated (10 mM iodoacetamide) and eluted in 0.1% trifluoroacetic acid. Peptides were purified using C18 columns and analyzed using an LTQ Orbitrap Velos Mass Spectrometer.

**Immunoblot to Confirm CADM-1 Differential Regulation**

Cultured EPCs were treated with TNFα (1 ng/ml)/control (PBS) for 3 hours and RCMVECs were treated with TNFα/control for 12 hours. Cells were isolated in a membrane prep buffer (255 mM sucrose, 20 mM HEPES, 1 mM EDTA) supplemented with protease inhibitor (Roche, Basel, Switzerland; http://www.roche.com) and lysed using a 24 gauge needle. Ten microgram of protein from each sample was loaded onto a 10% polyacrylamide gel (BioRad, Hercules, California; http://www.biorad.com) and transferred to a PVDF membrane. The membranes were blocked with nonfat dry milk and probed overnight with the CADM1 antibody (1:1,000, abcam ab3910, Cambridge, Massachusetts; http://www.abcam.com). Secondary probing was done using HRP conjugated goat anti-rabbit (BioRad, Hercules, California; http://www.bio-rad.com #170-6515, 1:5000) for 2 hours at 4°C. Visualization and development was done with chemiluminescence (Pierce, Thermo Fisher Scientific; Waltham, Massachusetts; http://www.thermofisher.com). The 55Kd bands were quantified based upon integrated optical density (Molecular Devices, Sunnyvale, California; http://www.moleculardevices.com). Results were normalized by staining the blot protein using a coomassie stain (BioRad, Hercules, California; http://www.bio-rad.com).

**NF-κB Inhibition**

EPC migration experiments were repeated using an NF-κB inhibitor. One hour prior to TNFα/vehicle treatment, a synthetic peptide NF-κB inhibitor (sc-3060; Santa Cruz Biotechnology, Dallas, Texas; http://www.scbt.com) or a control, scrambled peptide inhibitor (sc-3061; Santa Cruz Biotechnology, Dallas, Texas; http://www.scbt.com) was placed into cell culture media at 1 μg/ml. Following treatment, TNFα (1 ng/ml)/control (PBS) was administered for 3 hours. EPCs were harvested and used for the migration assay or RNA analysis.

**siRNA-Mediated CADM-1 Knockdown Experiments**

EPCs were isolated and cultured in 100 mm dishes. After 10 days of expansion, cells were transfected with ON-TARGETplus CADM1 siRNA (J-101011-12, Thermo Fisher Scientific; Waltham, Massachusetts; http://www.thermofisher.com) or the scrambled control (D-001810-02-05; Thermo Fisher Scientific; Waltham, Massachusetts; http://www.thermofisher.com) using DharmaFECT3 transfection reagent (T-2003-03; Thermo Scientific; Waltham, Massachusetts; http://www.thermofisher.com) according to the manufacturer’s instructions. Briefly, for a single dish, 6.3 μl of siRNA (20 μM) was mixed with 193.7 μl of opti-MEM reduced serum media (Invitrogen 31985062, Thermo Fisher Scientific; Waltham, Massachusetts; http://www.thermofisher.com) in one tube while 40 μl of DharmaFECT3 and 160 μl of opti-MEM reduced serum media (Invitrogen 31985062, Thermo Fisher Scientific; Waltham, Massachusetts; http://www.thermofisher.com) were mixed in a second. The two solutions were combined, incubated at room temperature for 20 minutes, and added to 4.6 ml of MCDB131 + EGM-2 media (without antibiotics). The transfection-ready mixture was added to the cell culture, yielding a final concentration of 25nM. After 24 hours of transfection, the media on the transfecting EPCs was changed to MCDB131 + EGM-2 (with antibiotics). After a further 24 hours, the cells were treated with TNFα (1 ng/ml) or vehicle (PBS) for 3 hours for use in the migration assay or RNA was isolation to assess knockdown efficiency.

**RESULTS**

**Expression of TNFα is Increased in an In Vivo Model of Electrically Stimulated Angiogenesis**

Previous work from both our group and others has demonstrated that electrically stimulating nerves innervating the hind-limb musculature induces angiogenesis in normal animals [42, 43]. In angiogenesis-incompetent animals, stimulating hind-muscle contractions after injecting EPCs restores impaired angiogenesis [36, 44]. The molecular mechanisms of angiogenesis in this model are not fully understood. It was hypothesized that TNFα was involved in this process. To test this hypothesis, Sprague Dawley rats were surgically implanted with hind limb stimulators that induced muscle twitching for 8 hours/day for 1 week. After 1 week, the tibialis anterior and EDL were harvested and expression of TNFα was measured using qPCR and ELISA. It was found that electrical stimulation significantly increased TNFα RNA by 65% and protein by 25% (Fig. 2A). The finding of increased TNFα expression in this model suggests that TNFα plays a key role in mediating EPC-induced angiogenesis. Based upon the role of TNFα in leukocyte recruitment, we hypothesized that TNFα increases the migratory activity of EPCs to the endothelium.

**TNFα Increases the Preferential Migration of EPCs Toward Vessel-Like Structures In Vitro**

To measure the migratory activity of EPCs, vessel-like structures were grown on a MatrigelTM based substrate using RCMVECs. EPCs were pretreated with TNFα or vehicle for 3 hours prior to suspending 1 x 10^6 DAPI stained EPCs in each well containing fully mature tubes. EPCs were pretreated in order to keep...

---

www.StemCells.com
conditions consistent with proteomic and gene expression experiments. Each well was imaged (brightfield and fluorescence in order to track both cell types) at 2 hours and 14 hours. The number and locations of each EPC was assessed to determine if it had migrated to a tube. It was found that TNFα pretreatment of EPCs significantly increased the fraction of EPCs that migrated to vessel-like structures at both 2 hours and 14 hours (Fig. 2B, 2C). The mechanism underlying this phenotype was further investigated with qPCR and proteomic analyses.

Figure 2. TNFα produced in an in vivo model of angiogenesis increases the migratory activity of EPCs in vitro. (A): TNFα expression is increased in an in vivo model of angiogenesis. A hind limb muscle stimulator that has previously been shown to induce angiogenesis was implanted and run for 7 days. After 7 days, RNA expression of TNFα was significantly increased in the stimulated limb vs the non-stimulated control (n = 6 per group). TNFα protein expression in homogenized hindlimb muscle (pg/mg of homogenized protein) was also found to be significantly upregulated in the stimulated versus the nonstimulated control (n = 6 per group). (B): In vitro EPC migration assay. Because TNFα expression was found to be increased in the angiogenic limb, EPCs were treated with TNFα/control and their locations were tracked with respect to capillary-like tubes in vitro. (C): Three hour, 1 ng/ml TNFα/vehicle pretreatment of EPCs increased the fraction that migrated toward tubes (p < .05) at 2 hours and 14 hours (n = 16 per group). Abbreviations: EPCs, endothelial progenitor cells; TNFα, tumor necrosis factor α.

Low Dose, Acute TNFα Treatment of EPCs Signals through the TNFRII (p75) Pathway, not the TNFR1 (p55) Pathway

TNFα is known to signal through two pathways, TNFRI (p55) and TNFRII (p75) [45, 46]. EPCs were treated with TNFα or vehicle and gene expression of key pathway components was measured using qPCR. In the p55 pathway, MADD, RIP, Caspase 2, and Caspase 3 were found to be significantly downregulated indicating attenuated apoptosis signaling. In the p75 pathway, TNFRII, TRAF3, and NF-κB were all found to be significantly upregulated. The canonical TNFα receptor pathway members were imported from Ingenuity Pathway Analysis and genes with significantly increased expression in response to TNFα were colored green whereas genes detected with significantly decreased expression were colored red (Fig. 3). As it has been demonstrated that NF-κB is activated through the TNFRII pathway, [47, 48] these results suggest increased migration of EPCs through TNFα treatment occurs primarily through the TNFRII (p75) pathway. This is further investigated through inhibition of NF-κB experiments.

NF-κB Mediates TNFα-Stimulated Migration to In Vitro Tubes

The results of Figure 3 suggested that TNFα-induced migration occurs through NF-κB. To test the hypothesis that NF-κB regulated genes transcription increases EPC migration, the migration assay was repeated using a peptide inhibitor of NF-κB or a scrambled-peptide control (Fig. 4). When using a control, it was found after both 2 and 14 hours that TNFα increased EPC migration to tube-like structures in vitro (p < .05). In the presence of the targeting NF-κB inhibitor, there was no change in migration toward tube-like structures at 2 hours and 14 hours. However, the increased migration induced by TNFα treatment was inhibited in EPCs pretreated with the NF-κB inhibitor compared to vehicle-treated cells, supporting the hypothesis that increased migration in response to TNFα treatment is mediated through NF-κB. As other studies have shown that NF-κB signaling in the TNF pathway is through the TNFRII receptor, these data, combined with those in Figure 3, support the hypothesis that TNF signaling in this system is occurring through the TNFRII receptor.

LC-MS/MS Identification of Unique Membrane Proteins that Mediate Migration

To identify effectors mediating the migratory phenotype induced by TNFα, EPC, and RCMVEC surface proteins were isolated and analyzed using LC-MS/MS. Four separate groups were analyzed (1. RCMVEC, control 2. RCMVEC, TNFα treated 3. EPCs, control 4. EPCs, TNFα treated). Relative protein abundance was quantified using spectral counting as previously described [36, 38].

Prior to candidate filtering using Visualize 1.58, [49] 6,000 unique proteins were identified. Approximately 1,000 of these proteins passed quality filters. The list was further filtered by eliminating proteins that did not participate in a relevant function (adhesion, incorporation, recruitment), were not differentially regulated in response to TNFα (p < .05), or where a binding partner was not identified in the complimentary cell type. In accordance with results from Figures 3 and 4, proteins had to be predicted in silico to be regulated by NF-κB.
using Genomatix Genome Analyzer (Genomatix Software GmbH; Munich Germany; http://www.genomatix.de) [50]. These criteria narrowed the candidate list to 7 candidate protein pairs (Table 1). Cell Adhesion Molecule 1 (CADM1) was chosen as the final candidate protein as it was demonstrated to have the largest up-regulation in response to TNF \(\alpha\) treatment and deficiencies in rodent models functionally matched the observed phenotype most closely [51–53].

**Confirmation of LC-MS/MS Results that CADM1 is Differentially Regulated in Response to TNF\(\alpha\)**

A sample LC-MS/MS spectra of a CADM1 specific peptide is shown in Figure 5A. Immunoblots of CADM1 in EPCs and RCMVECs were completed to validate CADM1 as a candidate protein to mediate the migratory process of EPCs (Fig. 5B). In EPCs, CADM1 expression was found to be significantly increased in response to TNF\(\alpha\), whereas in RCMVECs CADM1 expression was detected, but no differential regulation was found in response to TNF\(\alpha\).

**qPCR Analysis of CADM1 Expression in Response to TNF\(\alpha\)**

To test the hypothesis that TNF\(\alpha\) differentially regulates CADM1 via NF-\(\kappa\)B, expression of CADM1 was assessed via qPCR in the presence or absence of an NF-\(\kappa\)B synthetic peptide inhibitor (Fig. 6, Panel A). When EPCs were treated with an NF-\(\kappa\)B or a matched control (scrambled peptide) inhibitor, CADM1 expression was found to be differentially upregulated in response to TNF\(\alpha\) (\(p < .05\)). When EPCs were treated with TNF\(\alpha\) and the NF-\(\kappa\)B inhibitor, the increased CADM1 expression was eliminated confirming the hypothesis that CADM1 is differentially regulated by TNF\(\alpha\) through NF-\(\kappa\)B signaling.

**EPC Migration with CADM1 Knockdown**

To test the hypothesis that TNF\(\alpha\) induced up-regulation of CADM1 increases the migration of EPCs toward tube-like structures in vitro, the migration experiment was repeated using EPCs transfected with CADM1 siRNA or a scrambled control (Fig. 6B). In EPCs transfected with the scrambled control it was found after both 2 and 14 hours that TNF\(\alpha\) still preferentially increased EPC migration toward tube-like structures in vitro (\(p < .05\)). In EPCs transfected with targeting siRNA, migration toward tube-like structures was still observed at 2 hours and 14 hours, but a preferential increase from TNF\(\alpha\) treatment was inhibited, supporting the hypothesis that increased migration in response to TNF\(\alpha\) treatment is mediated through CADM1.


**DISCUSSION**

In this study, the molecular mechanism driving increased EPC migration in response to TNFα was investigated. Signaling was grouped into three categories: (1) receptors, (2) effectors, and (3) intracellular processing. It was found that TNFα signaling in EPCs was occurring through NF-κB stimulation from TNFR2. To study effectors, a proteomic study identified CADM1 as the highest priority candidate and its role in the migratory process was directly tested and confirmed. To study intracellular processing downstream of TNFR2, NF-κB blockade demonstrated an attenuated increase in migration in response to TNFα treatment. Finally, TNFα regulation of CADM1 through an NF-κB mediated mechanism was tested and confirmed by inhibiting NF-κB and measuring CADM1 gene expression.

**Migratory/Incorporation Phenotype**

It has been shown that very few cells are required to induce angiogenesis in animal models suggesting that a small subfraction of injected cells are responsible for the majority of observed therapeutic effects. Kaczorowski et al. demonstrated an injection of 500 EPCs induced angiogenesis in a model of hind limb ischemia, far too few cells to track with current imaging modalities [36]. In vivo tracking studies have shown that the cellular signal is cleared within hours of injection. In spite of this, regenerative effects are still observed [54]. Detection of little or no signal supports the finding that it takes very few cells to observe significant regenerative effects. In absence of a signal it is difficult to ascertain where these cells are migrating and when they are engrafting. Therefore, studies that utilize in vivo imaging of labeled EPCs do not directly observe EPC migration. To directly study EPC migration in vitro system was utilized that allowed for direct observation of migrating cells.

Several in vitro migration assays exist. Two examples are (1) the scratch assay, where a cellular monolayer is disrupted and an index of repair is measured and (2) the Boyden chamber assay, where cells are stimulated to migrate across a barrier with small pores [55]. The scratch assay is optimally suited for proliferating cells and the Boyden chamber assay is optimally suited for cells that migrate in response to a chemokine gradient. Because the EPCs in the present study were not proliferating and were pre-treated (as opposed to following a chemokine gradient), it was necessary to use a different assay. Asahara et al. demonstrated in a model of hind limb ischemia that injected EPCs preferentially migrated to the ischemic limb [7, 56]. The assay used in the present study mimicked in vivo migration quantifying the fraction of cells that had preferentially settled on a vessel-like structure. Similar to the in vivo work by Asahara et al., our results suggest that inflammatory cytokines secreted by the hind limb activate circulating EPCs increasing vessel incorporation (Fig. 2).

![Inhibition of NF-κB Reduces TNFα Induced Migration](image)

**Table 1.** Candidate migration protein pairs. After chemically isolating cell surface proteins and completing an LC-MS/MS analysis, over 6,000 proteins in total were identified. Quality filters narrowed the identified candidate list to 1,000 potential targets. Functional filters described in the text further narrowed down the candidate list to seven potential targets. Cell Adhesion Molecule 1 (CADM1) was chosen as the primary candidate because it met all criteria, had the largest increase in response to TNFα, and had the most biologically relevant function.

| Protein                                | Differentially regulated in | Observed binding partner | Binding partner differential regulation? | Normalized ratio | Normalized p value |
|----------------------------------------|-----------------------------|--------------------------|------------------------------------------|------------------|--------------------|
| Cell adhesion molecule 1               | EPCs                        | CADM1-4                  | Upregulated, Not significant               | 8.54             | 9.409E–08          |
| FRAS1-related extracellular matrix protein 3 | RCMVECs                    | Basement membrane (Laminins) | Yes, various forms detected                | 6.40             | 0.0029273          |
| PDZ domain-containing protein 3        | EPCs                        | Many                     | No                                       | 2.99             | 0.032395           |
| Junctional adhesion molecule A         | RCMVECs                    | MPDZ                     | No                                       | 2.24             | 2.144E–05          |
| Neural cell adhesion molecule 1        | RCMVECs                    | NCAM1                    | No                                       | 2.09             | 2.482E–04          |
| Neuroplastin                           | EPCs                        | Neuroplastin             | Yes                                      | TNFα Only        | 2.839E–11          |
| Afadin                                 | EPCs                        | Various actins           | Yes                                      | TNFα Only        | 4.113E–13          |

Abbreviations: TNFα, tumor necrosis factor α; EPC, endothelial progenitor cell; RCMVEC, Rat cardiac microvascular endothelial cells.
TNFα Signaling

TNFα signaling occurs through two receptors. Signaling through TNFR1 (p55) induces apoptosis, whereas signaling through TNFR2 (p75) induces NF-κB mediated gene transcription [45, 57–59]. Downstream signaling converges on several transcription factors, and the effect TNFα has on cellular activity has been shown to be a function of TNFα concentration, duration of exposure and cell type [60–65]. Kelly et al. studied the role of the TNF receptors in mesenchymal stem cell (MSC) mediated cardiac regeneration. Sequential knock-out of the TNF receptors showed that p55 signaling was detrimental and p75 was beneficial when using MSCs as a cellular-based therapy to improve cardiac function following myocardial infarction. Even more interesting was the finding that when the p75 receptor was mutated, cardiac recovery was reduced to levels observed with a vehicle injection [22]. These results demonstrate that TNFα signaling through the p75 receptor is necessary for MSC based regenerative therapy.
Results of the present study suggest that TNFα activation through p75 signaling induces increased EPC migration in vitro.

The results of the current study demonstrate that a low, acute dose of TNFα to EPCs serves to increase the migratory activity of EPCs through p75 activation of NF-κB. Clinically, these results are important in patients with diseases of increased or decreased angiogenesis. Increased angiogenesis is a feature of several types of cancer as increased levels of EPCs have been found in tumors in vivo [66, 67]. Disruption of the EPC migratory process would be beneficial to cancer patients as EPCs have been shown to enhance tumors proliferation. Decreased angiogenesis is a feature of ischemic diseases including angina pectoris and heart failure [68]. To translate these findings clinically, in diseases of increased angiogenesis it would be beneficial to maximize p55 signaling and in diseases of decreased angiogenesis it would be beneficial to maximize p75 signaling. This could be done by tailoring anti-inflammatory treatments for the individual patient or through the development of drugs that selectively block TNFα signaling at either the p55 or p75 receptor.

Kishore et al. demonstrated the importance of TNFα signaling through the p75 vs the p55 receptor in recovery from myocardial infarction (MI) [45]. To test the hypothesis that p75 signaling would be protective whereas p55 signaling would be harmful in MI recovery, the p55 and p75 receptors were knocked out (KO) in separate strains of mice. To test the hypothesis that p75 signaling would be protective whereas p55 signaling would be harmful in MI recovery, the p55 and p75 receptors were knocked out (KO) in separate strains of mice. Left anterior descending arteries were occluded to induce an MI and metrics of recovery were measured. In p55/KO mice, myocardial recovery was improved and in p75/KO mice, myocardial recovery was impaired. In that study, the distribution of the p55/p75 receptors was measured in tissues as a function of age and it was found that cardiac p75 receptor density decreased with age, suggesting that the ability to recover from an MI reduces with age due to reduced p75 signaling.

Kishore et al. also measured pro-angiogenic gene expression in EPCs isolated from elderly and young humans. It was found that EPCs isolated from younger humans expressed more pro-angiogenic genes. A follow up study by Sasi et al. demonstrated that EPCs isolated from elderly vs younger humans had less p75 expression. This finding was offered as explanation for the expression of lower angiogenic gene expression in cells isolated from elderly patients [69]. The results of these studies and the current study suggest that increased mortality from MI observed in the elderly [70] is due to attenuated EPC repair activity due to decreased angiogenic gene expression in EPCs. In Figure 1, it was proposed that cardiac damage is repaired through a negative-feedback

Figure 6. Analysis of CADM1 for a function role in endothelial progenitor cell (EPC) migration in response to TNFα. (A): PCR Analysis of CADM1 Expression in Response to Inhibitors. (1) CADM1 gene expression was measured in response to TNFα in the presence of a synthetic peptide inhibitor of NF-κB or the scrambled control. In presence of the scrambled control TNFα induced up regulation of CADM1 (p < .05) whereas in presence of the inhibitor this response was abolished. (2) In the presence of scrambled siRNA, TNFα was able to increase gene expression of CADM1 (p < .05) whereas in the presence of targeting siRNA this phenotype was abolished (n = 16 per group). (B): EPC migration with CADM1 knockdown. Prior to TNFα administration, EPCs were transfected with a CADM1 siRNA or a scrambled control. The TNFα induced migratory phenotype was still observed in the presence of the scrambled inhibitor at 2 hour and 14 hours (p < .05) but the phenotype was abolished at 2 hours and 14 hours when the targeted siRNA was transfected (n = 16 per group). Abbreviations: TNFα, tumor necrosis factor α.
system. These findings would suggest that aging and/or disease impairs the function of this regenerative system through differential expression of the p55/p75 receptors.

**CADM1: An Additional Role for a Versatile Protein?**

Cell Adhesion Molecule 1 is a protein that has been found to be strongly expressed in neurons, [71–75] spermatogenic cells, [52, 76–78] immune cells, [79–87] and endothelial cells [88, 89]. Functionally, CADM1 has been shown to participate in homophilic binding, and paradoxically, tumor suppression. It would be reasonable to hypothesize that CADM1-mediated adhesion of EPCs would increase tumor growth. However, members of the CADM family have an immune component, effectively suppressing tumor growth once in the bound form [90].

There exists an extensive body of literature describing CADM1 as a tumor suppressor protein, but only two studies that describe “CADM1” and its role in the vascular system [88, 89]. Hasstedt et al. was the follow-up on a human linkage study that had the goal of identifying single nucleotide polymorphisms (SNPs) in genes of the Kindred Vermont II family [89]. The Kindred Vermont II is a family of a couple born in Vermont in the 1830s that have increased susceptibility to venous thrombosis (VT) [91]. Prior to the study by Hasstedt et al. in 2009, a linkage analysis narrowed the VT causing region to an area of 109 genes [91, 92]. After analyzing the DNA sequences of the 109 genes identified in the disease-causing region, it was found that 8 CADM1 SNPs correlated with a patients’ risk for VT. These SNPs were shown to mutate the amino acids within the CADM1 protein, likely altering function. Either an increase or decrease in CADM1 binding kinetics could lead to improper recruitment of EPCs ultimately causing the development of vascular malformations and generation of clots [93].

Kaczorowski et al. compared angiogenic-competent and angiogenic-incompetent EPCs derived from two genetically distinct rat strains in an in vivo model of hind limb stimulation [36]. The angiogenic-incompetent EPCs were isolated from a salt-sensitive (SS/MCWi) rat and the angiogenic-competent EPCs were isolated from an SS-13BN/MCWi rat [94, 95]. In this study, it was found that $5 \times 10^5$ EPCs from the angiogenic-competent strain had the same therapeutic efficacy as $5 \times 10^5$ from the angiogenic-incompetent EPCs, indicating a 1,000-fold difference in therapeutic potency between the two strains. A proteomic analysis of surface proteins was conducted, investigating differential expression between the two strains. The conclusion was that the phenotype of impaired angiogenesis was due to increased immune reactivity toward EPCs derived from the SS/MCWi strain. In the proteomic analysis by Kaczorowski et al., CADM1 was found to be increased 10-fold in the SS/MCWi (impaired angiogenesis) compared to the SS-13BN/MCWi strain. These results indicate an important point, that successful adhesion and migration of EPCs are not the sole processes responsible for induction of angiogenesis. Successful migration is necessary for induction of angiogenesis, but additional steps with distinct mechanisms are also required for angiogenesis. In the context of human studies, it is important to note that EPCs isolated from a genetically heterogeneous population are likely to have large differences in therapeutic potency, illustrating the need for further research to develop clinical assays that can measure EPC potency prior to therapy.

**CONCLUSION**

In summary, EPC therapies are a promising clinical treatment. Prior to becoming a mainstream therapy, further research identifying the regenerative mechanisms is necessary to obtain consistent clinical results. To achieve this, studies need to be conducted to better understand the mechanisms of EPC-induced migration, binding, and regeneration. Results from this study indicate that TNFα signaling through TNFR2 that induces NF-κB and CADM1 transcription likely plays a role in the process of EPC migration to a site of organ damage in vivo. Our results suggest that the expression of molecular biomarkers (TNFR2, NF-κB, and CADM1) in EPCs could serve to effectively screen EPCs pre-therapy and potentially increase the success rates in human EPC trials.

**ACKNOWLEDGMENTS**

We would like to thank S.Z.P. for her help with manuscript preparation. This work was supported by NIH Grant HL082798 and a gift from the Kern Family Foundation. A.P. was supported in part by an MSTP Institutional Training Fellowship from NIGMS (T32 GM80202). B.H. was supported by HL94273, DK105043, and MCW RAC award funding. C.K. was supported by K99/00-AG-039511.

**AUTHOR CONTRIBUTIONS**

A.P.: Conception/design, Collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript. B.H.: Collection and/or assembly of data, data analysis and interpretation, final approval of manuscript. C.R.: Collection and/or assembly of data, data analysis and interpretation, final approval of manuscript. C.K.: Collection and/or assembly of data, data analysis and interpretation, final approval of manuscript. E.E.: Collection and/or assembly of data, data analysis and interpretation, final approval of manuscript. A.G.: Conception/design, financial support, data analysis and interpretation, manuscript writing, final approval of manuscript.

**DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST**

The authors indicate no potential conflicts of interest.

**REFERENCES**

1. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964–967.
2. Zuk PA, Zhu M, Mizuno H et al. Multi-lineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 2001;7:211–228.
3. Kawamoto A, Gwon HC, Iwaguro H et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001;103: 634–637.
4. Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 2004;364:141–148.
5. Kang HJ, Kim HS, Zhang SY et al. Effects of intracoronary infusion of peripheral blood
stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function after coronary stenting in myocardial infarction: The MAGIC cell randomised clinical trial. Lancet 2004;363:751–756.

6 Foley L, Whitaker M. Concise Review: Cell Therapies: The Route to Widespread Adoption. Stem Cells Transl Med 2012;1:438–447.

7 Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221–228.

8 Volaklis KA, Tokmakidis SP, Halle M. Acute and chronic effects of exercise on circulating endothelial progenitor cells in healthy and diseased patients. Clin Res Cardiol 2013;102:249–257.

9 Zhang W, Yan H. Simvastatin increases circulating endothelial progenitor cells and reduces the formation and progression of diabetic retinopathy in rats. Exp Eye Res 2012;105:1–8.

10 Ocera A, Aktas E, Yilmaz A et al. Decrease in endothelial progenitor cells associated with inflammation, but not with endothelial dysfunction in chronic hemodialysis patients. Clin Nephrol 2013;79:21–30.

11 Grundmann M, Woywodt A, Kirsch T et al. Circulating endothelial cells: A marker of vascular damage in patients with preeclampsia. Am J Obstet Gynecol 2008;198:317:311–315.

12 Zhou Y, Zhu J, Zou L et al. Changes in number and biological function of endothelial progenitor cells in hypertension disorder complicating pregnancy. J Huazhong Univ Sci Technol Med Sci 2008;28:670–673.

13 Zhou WJ, Zhu DL, Yang Y et al. Circulating endothelial progenitor cells in Chinese patients with acute stroke. Hypertens Res 2009;32:306–310.

14 Wang HY, Gao PJ, Ji KD et al. Circulating endothelial progenitor cells, C-reactive protein and severity of coronary stenosis in Chinese patients with coronary artery disease. Hypertens Res 2007;30:133–141.

15 Rodriguez-Ayala E, Yao Q, Holmen C et al. Imbalance between detached circulating endothelial cells and angiogenic and inflammatory cytokines during recovery from an episode of major depression. J Affect Disord 2012;136:1159–1163.

16 Prisco AR, Prisco MR, Carlson BE et al. TNF-alpha-induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1beta in vitro. J Surg Res 2007;142:13–19.

17 Ablin JN, Boguslawski V, Aloush V et al. Effect of anti-TNF or sTNF treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci 2006;79:2364–2369.

18 Kelly ML, Wang M, Crisostomo PR et al. TNF receptor 2, not TNF receptor 1, enhances mesenchymal stem cell-mediated cardiac protection following acute ischemia. Shock 2010;33:602–607.

19 Carswell EA, Old LJ, Kassel RL et al. An endothoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666–3670.

20 Gerstetter M, Garcia-Zepeda EA, Lim Y-C et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999;398:718–723.

21 LuskinSka PD, Francis W, Gimbreon Jr M, Michael A. Endothelial-dependent mechanisms in chronic inflammatory leukocyte recruitment. Annu Rev Med 1996;47:413–421.

22 LuskinSka FW, Kansas GS, Ding H et al. Monocyte rolling, arrest and spreading on IL-4-activated vascular endothelium under flow is mediated via sequential action of L-selectin, beta 1-integrins, and beta 2-integrins. J Cell Biol 1994;125:1417–1427.

23 Levy K, Baker J, Cybulsky M et al. Intravascular interleukin-8 inhibits granulocyte emigration from rabbit mesenteric venules without altering L-selectin expression or leukocyte rolling. J Immunol 1993;151:6347–6357.

24 Wyble CW, Hynes KL, Kuchibhotla J et al. TNF-x and IL-1 upregulate membrane-bound and soluble E-selectin through a common pathway. J Surg Res 1997;73:107–112.

25 Walsh Lj, Trinchieri G, Waldorf HA et al. Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelium leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991;88:4220–4224.

26 Sugarman BJ, Aggarwal BB, Hass PE et al. Recombinant human tumor necrosis factor-alpha: Effects on proliferation of normal and transformed cells in vitro. Science 1985;230:943–945.

27 McHale HJ, Harari OA, Marshall D et al. TNF-alpha and IL-1 sequentially induce endothelial ICAM-1 and VCAM-1 expression in MRL/lpr lupus-prone mice. J Immunol 1999;163:3993–4000.

28 McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989;9:349–351.

29 Shohani E, Novikov M, Bass R et al. Closed head injury triggers early production of TNF-x and IL-6 by brain tissue. J Cereb Blood Flow Metab 1994;14:615–619.

30 Gleeson M. Immune function in sport and exercise. J Appl Physiol 2007;103:693–699.

31 Redlich CA, Gao X, Rockwell S et al. IL-11 enhances survival and decreases TNF production after radiation-induced thoracic injury. J Immunol 1996;157:1705–1710.

32 Kaczorowski CC, Stigliani TJ, Hoffmann BR et al. Targeting the endothelial progenitor cell surface proteome to identify novel mechanisms that mediate angiogenic efficacy in a rodent model of vascular disease. Physiol Genomics 2013;45:999–1011.

33 Linderman JR, Kloehn MR, Greene AS. Development of an implantable muscle stimulator: Measurement of stimulated angiogenesis and poststimulus vessel regression. Microcirculation 2000;7:119–128.

34 Hoffmann BR, Wagner JR, Prisco AR et al. Vascular endothelial growth factor-A signaling in bone marrow-derived endothelial progenitor cells exposed to hypoxic stress. Physiol Genomics 2013;45:1021–1034.

35 Prisco AR, Bukowy JD, Hoffmann BR et al. Automated quantitative analysis reveals hyperglycemia inhibits endothelial angiogenic function. PLoS One 2014;9:e94599.

36 Wollscheid B, Bausch-Fluck D, Henderson C et al. Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol 2009;27:378–386.

37 Prisco A, Hoffmann BR, Kaczorowski CC et al. Targeted proteomics: Endothelial cell membrane response to TNF-x. FASEB J 2013;27:737.736.

38 Amaral SL, Linderman JR, Morse MM et al. Angiogenesis induced by electrical stimulation is mediated by angiotensin II and VEGF. Microcirculation 2001;8:57–67.

39 Linderman JR, Kloehn MR, Greene AS. Development of an implantable muscle stimulator: Measurement of stimulated angiogenesis and poststimulus vessel regression. Microcirculation 2000;7:119–128.

40 Karcher JR, Greene AS. Bone marrow mononuclear cell angiogenic competency is suppressed by a high salt diet. Am J Physiol Cell Physiol 2013;306:C123–C131.

41 Kishore R, Tkebuchava T, Sasi SP et al. Tumor necrosis factor-alpha signaling via TNFR1/p55 is deleterious whereas TNFR2/p75 signaling is protective in adult infarct myocardium. Adv Exp Med Biol 2011;691:433–448.

42 Neumann B, Machleidt T, Lifka A et al. Crucial role of 55-kilodalton TNF receptor in TNF-induced adhesion molecule expression and leukocyte infiltration. J Immunol 1996;158:1587–1593.

43 Munroe ME, Bishop GA. Role of tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) in distinct and overlapping CD40 and TNF receptor 2/CD120b-mediated B lymphocyte activation. J Biol Chem 2004;279:53222–53231.

44 Rauert H, Wycovksy A, Müller N et al. Membrane tumor necrosis factor (TNF) inducer p100 processing via TNF receptor-2 (TNFRF2). J Biol Chem 2010;285:7394–7404.

45 Malligan BD, Greene AS. Visualize: A free and open source multifunction tool for proteomics data analysis. Proteomics 2011;11:1058–1063.

46 Werner T. Bioinformatics applications for pathway analysis of microarray data. Curr Opin Biotechnol 2008;19:50–54.

47 Takayanagi Y, Fujita E, Yu Z et al. Impairment of social and emotional behaviors in
Cadm1-knockout mice. Biochem Biophys Res Commun 2010;396:703–708.

52 Wakayama T, Iseki S. Role of the spermatogenic–Sertoli cell interaction through cell adhesion molecule-1 (CADM1) in spermatogenesis. Anat Sci Int 2009;84(1):112–121.

53 Ito A, Ichiyanagi N, Ikeda Y et al. Adhesion molecule CADM1 contributes to gap junctional communication among pancreatic islet β-cells and prevents their excessive secretion of glucagon. Islets 2012;4:49–55.

54 Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 2012;110:624–637.

55 Kramer N, Walzl A, Unger C et al. In vitro cell migration and invasion assays. Mutat Res 2013;752:10–24.

56 Krasinski K, Spyridopoulos I, Asahara T et al. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997;95:1768–1772.

57 Sasi S, Yan X, Enderling H et al. Breaking the ‘harmony’ of TNF-α signaling for cancer treatment. Oncogene 2011;31:4117–4127.

58 Goukassian DA, Qin G, Dolan C et al. Tumor necrosis factor-α receptor p75 is required in ischemia-induced neovascularization. Circulation 2007;115:752–762.

59 Wang C, Deng L, Hong M et al. TAK1 is a ubiquitin-dependent kinase of MKK and Ikk. Nature 2001;412:346–351.

60 Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010;102:639–644.

61 Zeller CN, Wang Y, Markel TA et al. Role of tumor necrosis factor receptor 1 in sex differences of stem cell mediated cardioprotection. Ann Thorac Surg 2009;87:812–819.

62 Kim YS, Park HJ, Hong MH et al. TNF-alpha enhances engraftment of mesenchymal stem cells into infarcted myocardium. Front Biosci (Landmark Ed) 2009;14:2845–2856.

63 Sethi G, Sung B, Aggarwal BB. TNF: A master switch for inflammation in cancer. Front Biosci 2008;13:5094–5107.

64 Sun M, Chen M, Dawood F et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007;115:1398–1407.

65 Sarzi-Puttini P, Atzeni F, Shoenfeld Y et al. TNF-α, rheumatoid arthritis, and heart failure: A rheumatological dilemma. Autoimmun Rev 2005;4:153–161.

66 Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249–257.

67 Shaked Y, Ciarrocchi A, Franco M et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313:1785–1787.

68 Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653–660.

69 Sasi S, Song L, Park D et al. TNF-TNFRII/p75 signaling inhibits early and increases delayed nontargeted effects in bone marrow-derived endothelial progenitor cells. J Biol Chem 2014;289:14178–14193.

70 Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J 1986;111:383–390.

71 Robbins EM, Krupp AJ, Perez de Arce K et al. SynCAM 1 adhesion dynamically regulates synapse number and impacts plasticity and learning. Neuron 2010;68:894–906.

72 Fogel AI, Sari Y, Biederer T et al. Selective capability of SynCAM and neurexin for functional synapse assembly. J Neurosci 2005;25:260–270.

73 Biederer T, Sari Y, Mozhayeva M et al. SynCAM, a synaptic adhesion molecule that drives synapse assembly. Science 2002;297:1525–1531.

74 Koma Y, Ito A, Wakayama T et al. Cloning of a soluble isoform of the SgIGSF adhesion molecule that binds the extracellular domain of the membrane-bound isoform. Oncogene 2004;23:5687–5692.

75 Toshimori K. Sperm-Head Formation and the Adhesion Molecule spermatogenic immunoglobulin superfamily in the mouse testis. Histochem Cell Biol 2013;140:1525–1531.

76 Biederer T, Sari Y, Mozhayeva M et al. SynCAM, a synaptic adhesion molecule that drives synapse assembly. Science 2002;297:1525–1531.

77 Koma Y, Ito A, Wakayama T et al. Cloning of a soluble isoform of the SgIGSF adhesion molecule that binds the extracellular domain of the membrane-bound isoform. Oncogene 2004;23:5687–5692.

78 Toshimori K. Sperm-Head Formation and Factors Affecting It. Dynamics of the Mammalian Sperm Head. Berlin: Springer, 2009:17–25.

79 Biederer T, Sari Y, Mozhayeva M et al. SynCAM, a synaptic adhesion molecule that drives synapse assembly. Science 2002;297:1525–1531.

80 Lei W, Liu HB, Wang SB et al. Tumor suppressor TSLC1 is implicated in cell proliferation, invasion and apoptosis in laryngeal squamous cell carcinoma. Tumour Biol 2012;34:673–683.

81 Liu D, Feng X, Wu X et al. Tumor suppressor TSLC1 is implicated in cell proliferation, invasion and apoptosis in laryngeal squamous cell carcinoma. Tumour Biol 2012;34:673–683.